VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, presented its first in vivo proof-of-concept data and additional in vitro findings validating its BiTAC-ADC technology platform at the 17th World ADC Congress in San Diego. The in vivo study demonstrated significant tumor regression in a breast cancer model following a single 3 mg/kg dose, with no observed decrease in body weight. The results also showed that both BiTAC-ADC components were required to produce the intended tumor-specific response.
Additional in vitro studies demonstrated the platform’s ability to distinguish cancer cells from healthy cells, prevent the release of active toxins outside the tumor and target multiple cancer cell lines. The findings support the potential of BiTAC-ADCs to deliver efficacy comparable to conventional antibody-drug conjugates while offering a differentiated safety profile designed to reduce systemic toxicity.
These results are important because they provide the first in vivo validation of the BiTAC-ADC platform, suggesting that it could overcome a major limitation of conventional ADCs: off-target toxicity. By requiring both components to engage tumor cells, the platform may spare healthy tissues from damage, potentially improving patient outcomes and expanding the therapeutic window. This proof-of-concept data could accelerate VERAXA’s pipeline of ADCs and proprietary BiTAC formats into clinical development and attract further investment in the company’s next-generation antibody-based therapeutics.
VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology. The company is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. BiTAC(R) is a registered trademark of VERAXA Biotech GmbH.
To view the full press release, visit https://ibn.fm/cs8SW. The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA. Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer.
Certain statements in this article are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including the risks set forth under the heading “Risk Factors” discussed under the caption “Item 1A. Risk Factors” in Part I of the Company’s most recent Annual Report on Form 10-K or any updates discussed under the caption “Item 1A. Risk Factors” in Part II of the Company’s Quarterly Reports on Form 10-Q and in the Company’s other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this article in making an investment decision, which are based on information available to us on the date hereof. All parties undertake no duty to update this information unless required by law. View the original release on www.newmediawire.com.
